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Abstract
Purpose The PET tracer [18F]florbetapir is a specific fibrillar amyloid-beta (Aβ) biomarker. During the late scan phase
(> 40 min), it provides pathological information about Aβ status. Early scan phase (0–10 min) can provide FDG-‘like’ infor-
mation. The current investigation tested the feasibility of using florbetapir as a dual-phase biomarker in behavioural variant
frontotemporal dementia (bvFTD).
Methods Eight bvFTD patients underwent [18F]florbetapir and [18]FDG-PETscans. Additionally, ten healthy controls and ten AD
patients underwent florbetapir-PET only. PET data were acquired dynamically for 60-min post-injection. The bvFTD PET data
were used to define an optimal time window, representing blood flow-related pseudo-metabolism (‘pseudo-FDG’), of florbetapir
data that maximally correlated with the corresponding real FDG SUVR (40–60 min) in a composite neocortical FTD region.
Results A 2 to 5-min time window post-injection of the florbetapir-PET data provided the largest correlation (Pearson’s r = 0.79,
p = 0.02) to the FDG data. The pseudo-FDG images demonstrated strong internal consistency with actual FDG data and were also
visually consistent with the bvFTD patients’ hypometabolic profiles. The ability to identify bvFTD from blind visual rating of
pseudo-FDG images was consistent with previous reports using FDG data (sensitivity = 75%, specificity = 85%).
Conclusions This investigation demonstrates that early phase florbetapir uptake shows a reduction of frontal lobe perfusion in
bvFTD, similar to metabolic findings with FDG. Thus, dynamic florbetapir scans can serve as a dual-phase biomarker in
dementia patients to distinguish FTD from AD and cognitively normal elderly, removing the need for a separate FDG-PET scan
in challenging dementia cases.
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Introduction
Imaging biomarkers for dementia have been classified as either
indicating specific pathology, suchas amyloid imaging, or neu-
ronal damage, such as impaired glucose metabolism or tissue
atrophy [1]. Several studies have indicated that dynamic or
dual-phase amyloid-PET imaging can provide both types of
biomarker. Early phase tracer distribution in the brain during
the firstminutes after injectionmainly reflects regional cerebral
blood flow,which is closely coupledwith cerebral glucoseme-
tabolism in neurodegenerative disease.
Amyloid-PET biomarkers can enable differential diagnosis
between dementias [2, 3]. This is particularly true for
frontotemporal dementia (FTD),which does not typically pres-
ent with fibrillar amyloid-beta (Aβ) pathology. However, in
some FTD patients, fibrillar Aβ deposits may be present in
addition to the pathological hallmarks of FTD and the propor-
tionof caseswithbothpathologies increaseswithage [4], there-
fore an additional differential diagnostic marker is needed.
[18F]-2-fluoro-2-deoxyglucose (FDG) is an established
marker for neuronal injury showing frontotemporal
hypometabolism in FTD [5, 6]. Comparable reductions of
cerebral blood flow (CBF) in FTD have been observed with
single-photon emission tomography (SPECT) [7, 8]. The util-
ity of early phase distribution of the amyloid tracer
[11C]Pittsburgh Compound B (PIB), which is a marker of
CBF, in FTD has also been demonstrated [9]. Several studies
demonstrated that the early phase distribution of [18F]-labeled
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amyloid tracers, including [18F]florbetapir, show similar pat-
terns as FDG-PET in Alzheimer’s disease (AD) (see refer-
ences in [10]). In the present study, we investigated whether
images of early phase [18F]florbetapir may also replace FDG-
PET in patients with FTD. We therefore examined patients
with mild behavioural variant FTD (bvFTD) who received
both dynamic [18F]florbetapir- and FDG-PET scans.
Materials and methods
Participants
Eight bvFTD patients who met consensus criteria for FTD
[11] and were > 45 years old, ten cognitively normal (CN)
controls, and ten AD patients who met the NINCDS-
ADRDA diagnostic criteria [12] and were > 50 years old
were included. Both patient groups were required to have
a carer who could act as an informant, could accompany
the patient to research visits, and could act as a consultee
for any patients lacking capacity to consent. Screening for
comorbidities was performed and exclusion criteria in-
cluded other neurodegenerative diseases, clinically signif-
icant systemic disease, imaging abnormalities not related
to FTD/AD from MRI, recent/ongoing alcohol or sub-
stance abuse, clinically significant electrocardiogram ab-
normalities or laboratory evaluations, clinically significant
infectious disease (e.g. HIV), previous participation in a
clinical trial targeting Aβ pathology and severe drug al-
lergy or hypersensitivity. Overall, 40 individuals were
screened for enrolment in the study, 28 completed the
whole protocol. Of the 12 who dropped out, three with-
drew (two CN and one bvFTD), one was too ill to com-
plete (bvFTD), the rest were excluded for prolonged QTc
(> 450 ms, one CN and one bvFTD), florbetapir produc-
tion failures (two AD), chronic obstructive pulmonary dis-
ease (one CN), and for behavioural difficulties, e.g. agita-
tion (three bvFTD). The Newcastle and North Tyneside
NHS Research Ethics Committee and Administration of
Radioactive Substances Advisory Committee (ARSAC)
approved the study.
All participants underwent a battery of neuropsychological
tests, including the Mini–Mental State Examination (MMSE)
[12], Trail Making test [13], verbal fluency [14], Alzheimer’s
Disease Assessment Scale cognitive subscale (ADAS-cog)
[15], and the Clinical Dementia Rating (CDR) [16].
Participant characteristics and neuropsychological test scores
are reported in Table 1.
Image acquisition
During all scanning visits, all patients were accompanied by a
carer and experienced neurologist. A more detailed report of
scanning procedures was published in Kobylecki et al. [17]. In
brief, T1-weighted 3D volumes were acquired (3T, Philips
Achieva) for coregistration with PET and to define regions of
interest (ROIs).
Dynamic PETscans were acqu5ired after a 15-s slow bolus
injection of 288.3 ± 18.2MBq of [18F]florbetapir over 60min
on a high-resolution research tomograph (HRRT; CTI/
Siemens, Knoxville, TN, USA) in list mode. Frames (1 × 15,
1 × 5, 1 × 10, 3 × 30, 3 × 60, 3 × 120, 3 × 180 and 8 × 300 s)
were reconstructed using an ordered-subset expectation
maximisation (OSEM) algorithm, including corrections for
randomcounts, scatter andmeasured attenuation. Patientswith
bvFTD also received a 60-min dynamic [18F]FDG-PET scan
(injected dose 184.4 ± 5.4 MBq) within 14 days of the
[18F]florbetapir scan on the sameHRRTscanner.
Image analysis
In-house software (based on MATLAB, MathWorks) was used
to create PETsummed images from the dynamic florbetapir and
FDG data (from 40 to 60 min post-injection). T1-weighted MR
images were coregistered to the 40–60 min florbetapir PET
images using SPM12 (Wellcome Trust Centre for
Neuroimaging). Coregistered MR images were segmented
(via OldSegment in SPM12) into grey matter (GM), white mat-
ter (WM), and cerebrospinal fluid. A GM-specific, 83-region
digital atlas [18–20] in native florbetapir space was created for
each participant. The individual native-space brain atlases were
used to acquire regional values for the PET data. The bvFTD
participants’ FDG images were coregistered to the florbetapir
space T1 image; as such the GM-specific atlas generated pre-
viously was already aligned to the coregistered FDG image,
maintaining consistent volumes of interest for both radiotracers.
A flowchart depicting the processing pipeline is presented in
Supplementary Fig. 1.
An FTD ‘meta-region’ comprising 32 combined left and
right regions from the Hammers atlas [20] was generated fol-
lowing Rostomian et al’s approach [9] (see Supplementary
Table 1 for regions included in the meta-region and
Supplementary Fig. 2 for a visual representation of the meta-
region). For each participant and radiotracer, a weighted mean
GM ROI value was calculated from the meta-region.
For both FDG and early florbetapir images (0–11 min), re-
gional standardised uptake value ratios (SUVRs)were calculated
relative to the mean activity of the bilateral cerebellum GM. For
the late florbetapir images (40–60 min) SUVRs were calculated
using the mean whole cerebellum (GM+WM) as reference.
Identification of optimal time frame for ‘pseudo-FDG’
image
Thirty time windows were chosen to create pseudo-FDG
images from the florbetapir-PET images, one image for
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each time window: for each starting time, post-injection
(0 s, 20 s, 30 s, 1 min, 1.5 min, and 2 min), five different
time windows were created (4, 5, 7, 9, and 11 min), e.g.,
0–4, 0–5, 0–7, 0–9, and 0–11 min for start time 0 s. This
was performed for each bvFTD patient (n = 8). For each
column of eight SUVR values calculated from the bvFTD
meta-region (8 patients × 30 time windows), Pearson’s r
correlation values were calculated between the early
florbetapir images and the corresponding eight SUVR
values from the FDG SUVR image. This resulted in 30
correlation coefficients, one for each time window to FDG
comparison, i.e. pseudo-FDG correlated with FDG, 0–5
pseudo FDG correlated with FDG, etc.
The highest correlation (r = 0.794, p < 0.05; Supplementary
Fig. 3) was found to be 2–5 min post-injection and these im-
ages were used as pseudo-FDG images for further analysis.
BPM comparison of FTD ‘pseudo-FDG’ images
The pseudo-FDG SUVR images (bilateral cerebellum GM as
reference) were directly compared to the real FDG SUVR
images (bilateral cerebellum GM as reference) in a voxel-
wise analysis using the BPMe toolbox [21]. The SUVR im-
ages were first spatially normalised into stereotactic MNI
space and smoothed by 6mm. BPM results were not corrected
for multiple comparisons (k = 50 voxels, p = 0.01).
SPM group comparison of ‘pseudo-FDG’ images
The pseudo-FDG bvFTD SUVR images were compared to
the CN and AD groups. Using SPM12, two-sample t tests
were conducted to identify any differences in the topograph-
ical pattern(s) between groups. SPM results were not corrected
for multiple comparisons (k = 50 voxels, p = 0.001).
All SPM and BPM results were visualised with the
BrainNet Viewer [22] displaying t- and r-values, respectively.
Table 1 Participant characteristics and demographic data
Characteristic CN bvFTD AD Statistic
Age (years) 62.5 (5.2) 62.5 (9.6) 62.6 (4.5) ns
Sex (% M) 40 100 70 7.24, p < 0.05 (Fisher’s exact test)
Length of disease (months) – 55.5 (20.5) 59.1 (20.9) ns
Mean education level
(0 = elementary; 3 = university)
2.4 (0.7) 2.5 (0.9) 1.6 (1.1) ns
MMSE 30.00 25.4 (5.1) 18.2 (5.7) F(2,25) = 8.8, p = 0.001
ADAS-Cog Recall 1.90 (1.0) 9.50 (12.6) 6.90 (2.1) ns
ADAS-Cog Naming 0.0 1.13 (1.8) 1.50 (2.1) ns
ADAS-Cog Drawing 0.0 1.13 (1.6) 1.40 (1.7) ns
Total ADAS-Cog Total score 3.0 (2.0) 18.1 (22.2) 28.0 (13.3) F(2,25) = 7.8, p < 0.01
Trail Making A time (s) 24.6 (8.5) 62.0 (39.8) 97.2 (53.1) F(2,25) = 8.9, p = 0.001
Trail Making B time (s) 48.0 (15.1) 140.9 (102.5) 238.2 (101.7) F(2,25) = 13.4, p = 0.001
Verbal fluency
Animals 22.4 (6.8) 11.4 (8.1) 11.2 (5.5) F(2,25) = 8.7, p = 0.001
Vegetables 13.3 (3.5) 6.9 (4.9) 6.5 (5.0) F(2,25) = 7.0, p < 0.01
CDR - Memory score – 0.7 (0.9) 1.4 (0.5) ns
Total CDR score – 1.1 (0.6) 1.0 (0.6) ns
Mean neocortical florbetapir (SUVR) 1.12 (0.08) 1.12 (0.27) 1.54 (0.26) F(2,25) = 11.7, p < 0.001
ApoE ɛ4 carriers – 4 6 ns
All data are mean (SD); ns not significant, MMSEMini-Mental State Examination, ADAS-CogAlzheimer’s Disease Assessment Scale cognitive
subscale, CDR clinical dementia rating, SUVR standardised uptake value ratio, ApoE apolipoprotein
Table 2 Region by region, within participant Pearson’s correlations
between pseudo-FDG and FDG SUVRs in the bvFTD patients
Patient Whole brain (83 regions) Meta-FTD region
(32 regions)
FTD1 0.94 0.94
FTD2 0.86 0.86
FTD3 0.72 0.78
FTD4 0.85 0.93
FTD5 0.83 0.93
FTD6 0.66 0.70
FTD7 0.92 0.97
FTD8 0.94 0.95
Mean 0.84 (0.09) 0.88 (0.09)
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Statistics
Analyses were performed with SPSS Version 22.0 (Statistical
Package for the Social Sciences, IBM, Armonk, NY). One-
way ANOVAs were performed on the neuropsychological
tests. The Kruskal–Wallis test was performed for sex and ed-
ucation level. Normality of data was assessed using the
Kolmogorov–Smirnov and Shapiro–Wilk tests, and homoge-
neity of variance was assessed using Levene’s test.
A within-participant region-by-region correlation (across
the whole-brain and meta-FTD regions) was performed be-
tween the pseudo-FDG and FDG images in the bvFTD pa-
tients. To compare methods, a Bland–Altman plot [23] was
constructed comparing pseudo-FDG images to FDG images,
in the bvFTD patients within the meta-FTD region.
Results
Participants
Participants did not differ significantly in age but there was a
difference in sex due to the all-male bvFTD cohort. MMSE
scores were lowest for the AD patients Table 1.
Correlation between FDG and pseudo-FDG
Inter-individual correlation between FDG and pseudo-FDG
(florbetapir 2–5 min) in the whole meta-FTD region was sig-
nificant, r = 0.63, p < 0.05. For this time frame, the mean cor-
relations of regional distributions in pseudo-FDG images and
FDG images within bvFTD patients were r = 0.84, p = 0.01
and r = 0.88, p = 0.01 for all brain regions, and when restricted
to ROIs within the meta-FTD region respectively (Table 2).
The Bland–Altman plot (Fig. 1) indicated that all values lied
within ± 1.96 SD of the mean, showing good internal consis-
tency between pseudo-FDG and FDG methods.
Fig. 1 Bland–Altman plot measuring the agreement between the pseudo-
FDG and FDG SUVRs in the meta-FTD region from the bvFTD patients.
A zero difference would indicate both methods provide the same result;
all values lie within 95% confidence limits
Fig. 2 Surface renderings of
BPM voxel-wise correlations for
bvFTD FDG vs pseudo-FDG
SUVR images; k = 50 voxels, p =
0.01 uncorrected, 6-mm
smoothing. The colour bar
represents r values. Positive
neocortical correlations are
present within the same frontal
and anterior temporal cortical
regions contained in the FTD
meta-region. Additional
correlations are also observed in
regions that include bilateral
inferior temporal gyrus, left
middle temporal, left superior
temporal, and left angular gyri
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Voxel-wise BPM whole-brain correlations
between FDG and pseudo-FDG
Positive neocortical correlations were present within the same
frontal and anterior temporal cortical regions contained in the
FTD meta-region (Fig. 2). Additional correlations were also
observed in regions that include bilateral inferior temporal
gyrus, left middle temporal, left superior temporal, and left
angular gyri. No significant negative correlations were
observed.
Visual assessment of PET images
Excellent visual correspondence was found between the
pseudo-FDG and FDG images in bvFTD (Fig. 3) and
individual patterns of hypometabolism were clearly
visualised in both image types. Overall, the pseudo-FDG
images had lower SUVR values and were qualitatively
noisier. Blind visual rating, without prior knowledge of
Aβ or Apolipoprotein E (ApoE) status, of all pseudo-
FDG SUVR images (CN, AD, and bvFTD) by a clinical
FDG expert (KH) matched the clinical diagnosis in 71%
(20/28) of individuals (dementia present, bvFTD, and AD,
sensitivity 82.4% (CI 56.6–96.2) and specificity 60% (CI
26.2–87.8). When classifying as FTD or non-FTD (CN +
AD) there were three false positives (two CN and one AD
rated as bvFTD) and two false negatives (two bvFTD as
CN), sensitivity 75% (CI 34.9–96.8) and specificity 85%
(CI 62.1–96.8).
SPM group analyses
For the pseudo5-FDG SUVR images, bvFTD patients
showed regional reductions consistent with expected
hypometabolic patterns relative to CN throughout the
neocortex particularly in the medial frontal and anterior
temporal lobes (Fig. 4). The contrast bvFTD vs. AD
produced a bilateral medial frontal pattern, with differ-
ences in the left anterior and medial temporal lobe
(Fig. 5).
Fig. 3 All imaging data from the
bvFTD patients is displayed.
Each row represents data from a
single patient; each column
represents coregistered images in
axial and coronal slices for T1
MRI, florbetapir, FDG, and
pseudo-FDG. The Colour bars
represent SUVR values. A clear
visual correspondence is seen in
the hypometabolic patterns from
the FDG images and the pseudo-
FDG images
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Discussion
To our knowledge, this is the first study to demonstrate that
the initial uptake of florbetapir provides a diagnostic signal
similar to FDG in patients with bvFTD. Similar results
have been obtained previously with PIB in FTD patients
and with various amyloid tracers, including florbetapir, in
AD patients. We believe that the early florbetapir frames
provide important complementary diagnostic information
to Aβ deposition, shown by late florbetapir frames, which
may be present not only in patients with AD, but also
cognitively normal elderly and occasionally as secondary
pathology in other neurodegenerative diseases, including
FTD [4].
Fig. 5 Surface renderings of SPM
t test for AD > bvFTD (pseudo-
FDG; florbetapir 2–5 min
SUVR); k = 50 voxels, p = 0.001
uncorrected, 6-mm smoothing.
The colour bar represents t
values. A clear medial frontal
pattern of hypometabolism is seen
between the patient groups, with
differences also in anterior
temporal and occipital cortex
Fig. 4 Surface renderings of SPM
t test for CN > bvFTD (pseudo-
FDG; florbetapir 2–5 min
SUVR); k = 50 voxels, p = 0.001
uncorrected, 6-mm smoothing.
The colour bar represents t
values. For the pseudo-FDG
images a clear pattern of frontal
and anterior temporal
hypometabolism is visually
evident
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The optimal time frame in this investigation of 2–5 min is
slightly different but largely overlappingwith findings reported
by Hsiao et al. [24] in AD patients. The interval chosen in their
study (1–6 min) resulted in a high correlation with FDG.
Patient selection, PET scanner type, and details of injection
speed and timing of dynamic scan start may explain the minor
time difference. Generally, all time intervals starting 1 min
post-injection up to 8 min gave strong and significant correla-
tions with marginal differences in r values. We also found that
straightforward calculation of SUVR is sufficient, producing
results that are very similar to calculations of R1 by dynamic
uptake modeling (Supplementary Fig. 4). Within-participant
correlations of pseudo-FDG and FDG distributions (Table 2)
were similar to published studies [9, 24, 25]. They were higher
than between-participant correlations of values in composite
ROIs representing variance caused by differences in the overall
supratentorial to infratentorial tracer uptake, which was sys-
tematically higher with FDG than with early florbetapir. The
Bland–Altman plot suggested that the close relationship be-
tween regional patterns between methods did not depend on
regional mean values.
In correspondence with close numerical correlation, there
was also generally excellent visual correspondence between
FDG and pseudo-FDG images (Fig. 3). As to be expected in
mild-to-moderate bvFTD, frontal hypometabolism was mild
in most patients. With both techniques, only one patient
(FTD2) showed pronounced asymmetric frontal hypoactivity,
while normal frontal activity was seen in another (FTD4).
Other patients showed mostly fronto-mesial hypoactivity,
which appeared slightly more pronounced on pseudo-FDG
than on FDG in two patients (FTD3, FTD6). It is, however,
not clear whether this would indicate higher sensitivity, be-
cause blood flow images may show higher variation than
FDG images even in normal subjects.
SPM analysis of pseudo-FDG in bvFTD patients versus
controls and versus AD showed the typical frontal reduction
frequently described in the literature and also seen with FDG
in the present study. Visual ratings demonstrated good sensi-
tivity and specificity of the findings for bvFTD, which were in
the same range as published data for FDG [26–28] and
HMPAO SPECT [8]. In the visual rater’s notes, both bvFTD
patients misclassified as CNs were suggested as “possible
mild FTD”. Notably, frontal reductions of early uptake similar
to FDGwas also seen in the single FTD patient (FTD8; Fig. 3)
who was amyloid positive on late scans, probably related to
the genetic status of homozygous ApoE4 positivity as report-
ed by Kobylecki et al. [17].
Kobylecki et al. [17] originally acquired the data used in
the present study; as such, the data available were not
optimised to achieve the primary objective, establishing if
early phase florbetapir could replace FDG. Kobylecki et al.’s
primary objective was to compare neocortical florbetapir in
FTD vs. CN and AD and consequently did not acquire FDG
data from the CN and AD control groups. For the present
study’s primary objective, having more data available for the
optimisation step (florbetapir and FDG data from all partici-
pants) would have enhanced this step since it was only per-
formed on eight bvFTD patients. Only eight bvFTD patients
being included in the present study is also a reflection of this
challenging patient population and the difficulties of identify-
ing suitable patients who could complete a very demanding
study protocol. Three bvFTD were excluded because their
behavioural symptoms were too severe to complete the study.
In real-world clinical practice, it would be unfeasible to per-
form such an intensive protocol in bvFTD patients. However,
the goal of this study was to provide evidence that dual-phase
florbetapir can provide complementary Aβ and pseudo-
metabolic information from a single PETscan, thus ultimately
reducing patient burden.
While the investigation of patient management was outside
the scope of the current work, current diagnostic research
criteria indicate that amyloid-PET and FDG-PET have a com-
plimentary diagnostic role and the data presented here dem-
onstrate the technical feasibility of obtaining both types of
images from a single dynamic florbetapir-PET scan, which
will negate the need of an additional FDG-PET scan in diag-
nostically challenging dementia cases.
Conclusions
This investigation demonstrates that the early frames of
florbetapir uptake show a reduction of frontal lobe perfusion in
bvFTD, similar to metabolic findings with FDG. Thus, dynamic
florbetapir can serve as a dual biomarker in dementia patients to
distinguish FTD from AD and cognitively normal elderly.
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